ACHP Letter to Acting FDA Commissioner on the Accelerated Approval of Drugs and Biologics
ACHP sent a letter to FDA’s Acting Commissioner, Sara Brenner, with comments on the Expedited Program for Serious Conditions.
ACHP sent a letter to FDA’s Acting Commissioner, Sara Brenner, with comments on the Expedited Program for Serious Conditions.
ACHP responded to a congressional RFI on legislation to advance emerging therapies and ease health information technology burdens
To ensure the use of AI technology in health care will improve patient outcomes and create a more sustainable and accessible health care system, public policy must support its innovation and safe use.
To address challenges in AI advancement in health care, ACHP is promoting three key principles that are essential to appropriate and effective oversight.
ACHP submitted a response to an RFI from HHS on strengthening the value of Medicare Advantage data.
